Citicoline

AOR04294

The only citicoline backed by 95+ clinical trials

  • Promotes phospholipid balance in the brain
  • Enhances neurotransmitter production
  • Supports brain structure
MyBlueprint™
Gluten Free
Non-GMO
Vegan

$59.94 or subscribe and save 20%

In stock

Choose a purchase plan:

Citicoline is cytidine diphosphate choline, or CDP-choline, a nutrient that has been shown to support memory in patients with age-associated memory impairment, and brain cell recovery from injuries such as stroke or concussion. Citicoline also increases the production of key neurotransmitters, including acetylcholine, norepinephrine, dopamine, and serotonin, all of which are essential for mood balance and memory. Additionally, it supports nerves in the eye, and studies administering Citicoline to patients with lazy-eye and other vision disorders have noted beneficial results.

The main component of Citicoline is its cytidine group, which is what Citicoline delivers to the brain. Rather than just supplying a single phospholipid, Citicoline boosts the brain’s  production of its own array of  phospholipids, including phosphatidylserine (PS), phospatidylcholine (PC), phosphatidylinositol (PI) and phosphatidylethanolamine (PE). Phospholipids are fundamental in the synthesis of neurotransmitters and the proper functioning of neural cell membranes – both highly significant factors for healthy cognitive function.

 

AOR Advantage

AOR’s Citicoline provides a source of choline along with added choline for enhanced acetylcholine production, while the cytidine end is converted into cytidine diphosphate which enhances the natural production of all the body’s phospholipids in a balanced manner.  Citicoline is ideal for those looking to support cognitive performance, memory, and mood, or to support the health and function of brain cells during aging or after a brain injury.

NPN

80033996

Discussion

Citicoline is cytidine 5’-diphosphate choline which promotes the synthesis of phosphatidylcholine as well as other phospholipids like phosphatidylserine. Phospholipids serve many beneficial roles within the brain.

Guarantees

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take two capsules one to two times daily, or as directed by a qualified health care practitioner.

Cautions

Do not use if you are pregnant or breastfeeding. Consult a health care practitioner for use beyond three months.

Main Applications
  • Cognitive function
  • Neurological support
  • Healthy memory function
  • Optical nerve support
Disclaimer

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Capsule
Xerenoos Citicoline (Cytidine 5'-diphosphate)
250 mg
Choline (as choline bitartrate)
14 mg

XERENOOS® is a trademark of INTERQUIM, S.A d.b.a Ferrer Healthtech

Non-medicinal Ingredients: microcrystalline cellulose, silicon dioxide.

Capsule: hypromellose, glycerin and purified water.

Cognitive Health
Study #1: Improves memory and cognition in patients with Alzheimer’s disease
A double-blind, placebo-controlled study tested the efficacy of citicoline supplementation on patients with Alzheimer’s disease. 30 patients with mild to moderate senile dementia (Alzheimer’s type) were randomized to receive 1000mg of citicoline for 12 weeks. Patients treated with citicoline showed significant improvements in cognitive performance. Supplementation also significantly increased cerebral blood flow compared to placebo.

Alvarez XA, Mouzo R, Pichel V, et al. (1999). Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 21(9):633-44

Study #2: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease

In a retrospective multicenter, case-control study, 448 patients with Alzheimer’s disease were treated either with an acetylcholinesterase inhibitor (AChEI) drug only, or the AChEI drug plus 1000mg of citicoline daily for nine months. There was a significant increase in Mini-Mental State Examination scores in patients given citicoline at the three-month mark and between the three- and nine-month mark. Researchers concluded that that the combined administration may slow the progression of Alzheimer’s disease.

Gareri P, Castagna A, Cotroneo AM, et al. (2017). The citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study. J Alzheimers Dis. 56(2): 557-565

Study #3: Citicoline improves verbal memory in aging

In a randomized, double-blind placebo-controlled study 95 subjects with inefficient memories were randomized to 1000mg of citicoline for three months. Afterwards a crossover study was conducted and 32 subjects from the initial group were given both placebo and 2000mg of citicoline, each for two months. In the first study, subjects with relatively inefficient memories, that were given citicoline, had improvements in delayed recall on logical memory. In the crossover study, researchers reported that subjects on the higher dose of citicoline had improved immediate and delayed logical memory.

Spiers PA, Myers D, Hochanadel GS, et al. (1996). Citicoline improves verbal memory in aging. Arch Neurol. 53(5): 411-8

Improves Vision
Study #1: Citicoline for neuroenhancement and neuroprotection

Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when blood flow is restricted from the optic nerve, causing unilateral vision loss. In this study, patients with NAION were randomized to receive an oral solution containing 500mg citicoline daily for six months. Twenty age-matched controls were also enrolled. A three-month washout period was then conducted in the treatment group (NC group). Of the original NAION patients enrolled, 17 received no treatment (NN group) for the nine months of the study. After the six-month treatment period, the NC group showed improvements in visual acuity, pattern electroretinogram responses, and visual evoked potentials, and these were significantly different from the NN group (p>0.01). Meanwhile all parameters in the NN group worsened.

Parisi V, Barbano L, Di Renzo A, et al. (2019). Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: a randomized pilot study. PLoS One. 14(7): e0220435

Study #2: Oral citicoline treatment improves visual pathway function in glaucoma

Intramuscular injections of citicoline have been shown to improve “visual evoked potentials” – a finding common in ocular hypertension or glaucoma – which can suggest slower nerve conduction in the visual pathways. A later study tested whether or not this would be reproduced by supplementing with citicoline orally. Patients with glaucoma (a total of 21 glaucomatous eyes) were given 1 gram of citicoline daily for two weeks. Citicoline supplementation led to visual benefits in 62% of the eyes treated. Significant improvements were seen in parameters of visual evoked potentials.

Rejdak, R, Toczolowski J, Kurkowski, J, et al. (2003). Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit. 9(3): PI24-8

Study #3: Citicoline improves retinal and cortical responses

In a randomized clinical trial, 40 patients with open-angle glaucoma were randomized to receive 1000mg daily of citicoline, via IM injection, or placebo for 60 days. Patients given citicoline had significant improvements in visual evoked potentials and pattern-electroretinograms (p<0.01) and these were also significantly different from those in patients given placebo (p<0.01).

Parisi V, Manni G, Colacino G, Bucci MG. (1999). Cytidine-5’-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Opthalmology. 106(6): 1126-34

Improves Motor Function
Study #1: Citicoline in the treatment of Parkinson’s disease

Patients with Parkinson’s disease who were taking levodopa were randomized to receive either 1200mg of citicoline daily in addition to their regular dose of medication, or citicoline plus only half the dose of levodopa. The patients that took a reduced medication dose, but not those with their regular dosage, with citicoline had improvements on several tests such as writing, drawing and walking. Researchers concluded that citicoline may be beneficial in reducing the dose of levodopa in patients with Parkinson’s. This could also help decrease the incidence of side effects and mitigate the effects of levodopa losing effectiveness with long-term treatment.

Eberhardt R, Birbamer G, Gerstenbrand F, et al. (1990). Citicoline in the treatment of Parkinson’s disease. Clin Ther. 12(6): 489-95

Study #2: Citicoline supplementation on motor speed and attention in adolescent males.

In a study of 75 healthy adolescent males, subjects were randomized to receive either 250mg or 500mg of citicoline, or placebo. Researchers conducted an attention test, “finger tap” test, and a computerized performance test and found that those given citicoline showed significant improvements in attention and psychomotor speed compared to subjects given placebo.

McGlade E, Agoston AM, DiMuzio J, et al. (2015). The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 23(2): 121-134

Study #3: Citicoline in the treatment of essential tremor

In an open study, 18 patients with essential bilateral tremor, patients were given 400mg daily of citicoline daily. After eight weeks of treatment, improvements in tremor severity were seen in 89% of patients, with 39% showing marked improvement (above 51% on the Clinical Rating Scale for Tremor – CRST)

Mubaidin A, Al-Swairi A-R, Nofal R, Wreikat A. (2011) Citicoline in the treatment of essential tremor. J Royal Med Services. 18(1): 20-5